================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                               ------------------

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

                               ------------------


                Date of Report (Date of earliest event reported):
                                  MAY 17, 2004


                         BIOSANTE PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)



          DELAWARE                       1-31812                 58-2301143
(State or Other Jurisdiction    (Commission File Number)     (I.R.S. Employer
      of Incorporation)                                   Identification Number)


         111 BARCLAY BOULEVARD
         LINCOLNSHIRE, ILLINOIS                                    60069
(Address of Principal Executive Offices)                         (Zip Code)


                                 (847) 478-0500
              (Registrant's Telephone Number, Including Area Code)



                                       N/A
          (Former Name or Former Address, If Changed Since Last Report)

================================================================================




ITEM 12.   RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

           On May 17, 2004, BioSante Pharmaceuticals, Inc. announced its
           financial results for the first quarter ended March 31, 2004.
           Attached to this Current Report on Form 8-K as Exhibit 99.1 is a copy
           of BioSante Pharmaceutical's press release in connection with the
           announcement. The information in this report is being furnished and
           shall not be deemed to be filed for purposes of Section 18 of the
           Securities Exchange Act of 1934, or otherwise subject to the
           liability of that section, and shall not be deemed to be incorporated
           by reference by any general statements by BioSante Pharmaceuticals,
           Inc. incorporating by reference this report or future filings into
           any filings under the Securities Act of 1933 or the Securities
           Exchange Act of 1934, except to the extent BioSante Pharmaceuticals,
           Inc. specifically incorporates the information by reference.








                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                    BIOSANTE PHARMACEUTICALS, INC.



                                    By:      /s/ Phillip B. Donenberg
                                       ----------------------------------------
                                        Phillip B. Donenberg
                                        Chief Financial Officer,
                                        Treasurer and Secretary
Dated:   May 17, 2004